Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728936 · ClinicalTrials.gov registry record · Phase 1
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
A Phase 1 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00728936: Completed Phase 1 study, sponsored by Idera Pharmaceuticals.
NCT00728936 is a Phase 1 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728936, a Phase 1 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
Primary Outcome
Count and percentage of subjects with treatment emergent adverse events
Interventions
- DRUG Saline placebo
- DRUG IMO-2125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00728936 record still lists
NCT00728936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Saline placebo is the first listed.
NCT00728936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00728936 about?
NCT00728936 is a clinical study titled "Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients". First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
What is the current status of trial NCT00728936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2007-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00728936?
The interventions under investigation include: Saline placebo (DRUG), IMO-2125 (DRUG).
Who is sponsoring clinical trial NCT00728936?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00728936's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia